APR 22, 2019 8:49 PM PDT

First Generic Naloxone Nasal Spray Approved To Treat Opioid Overdose

WRITTEN BY: Nouran Amin

The U.S. Food and Drug Administration has approved the first generic naloxone hydrochloride nasal spray. The spray is called Narcan and is a life-saving medication that can stop or reverse the effects of an opioid overdose.

According to the Centers for Disease Control and Prevention, about 400,000 people have died from an opioid overdose between 1999 to 2017. On average, 130 Americans die every day from opioid overdoses--a class of drugs that include prescription medications such as fentanyl, oxycodone, hydrocodone and morphine. Some opioids include illegal drugs such as heroin which contains fentanyl or derivatives of fentanyl.

“In the wake of the opioid crisis, a number of efforts are underway to make this emergency overdose reversal treatment more readily available and more accessible. In addition to this approval of the first generic naloxone nasal spray, moving forward we will prioritize our review of generic drug applications for naloxone. The FDA has also taken the unprecedented step of helping to assist manufacturers to pursue approval of an over-the-counter naloxone product and is exploring other ways to increase the availability of naloxone products intended for use in the community, including whether naloxone should be co-prescribed with all or some opioid prescriptions to reduce the risk of overdose death,” said Douglas Throckmorton, M.D., deputy center director for regulatory programs in the FDA’s Center for Drug Evaluation and Research.

“All together, these efforts have the potential to put a vital tool for combatting opioid overdose in the hands of those who need it most – friends and families of opioid users, as well as first responders and community-based organizations. We’re taking many steps to improve availability of naloxone products, and we’re committed to working with other federal, state and local officials as well as health care providers, patients and communities across the country to combat the staggering human and economic toll created by opioid abuse and addiction.”

Source: FDA

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
JUN 06, 2022
Cannabis Sciences
Price and Convenience: Key Reasons Why People Continue to Buy Illegal Cannabis
JUN 06, 2022
Price and Convenience: Key Reasons Why People Continue to Buy Illegal Cannabis
A study published in the Journal of Studies on Alcohol and Drugs found that price and convenience are the two main reaso ...
JUN 06, 2022
Immunology
Using Antibodies to Create Potent Cancer Treatments
JUN 06, 2022
Using Antibodies to Create Potent Cancer Treatments
Cancer can arise from a variety of aberrations that cause cells to divide uncontrollably, and form a tumor. The causes o ...
JUN 16, 2022
Cancer
Dance/Movement Therapy Benefits Cancer Patients
JUN 16, 2022
Dance/Movement Therapy Benefits Cancer Patients
For cancer treatment, standard of care (sometimes referred to as best practice or standard therapy) defines medical trea ...
JUL 01, 2022
Coronavirus
Nanobodies Could Protect Us From Every Variant
JUL 01, 2022
Nanobodies Could Protect Us From Every Variant
Immune reactive molecules called nanobodies, which are based on molecules found in llamas could offer robust protection ...
JUL 14, 2022
Clinical & Molecular DX
Emerging Research Could Soon Solve the Parkinson's Disease Diagnosis Challenge
JUL 14, 2022
Emerging Research Could Soon Solve the Parkinson's Disease Diagnosis Challenge
Parkinson’s disease is a brain disorder with symptoms that begin gradually and worsen over time. Symptoms of Parki ...
AUG 07, 2022
Neuroscience
Physiotherapy Technique Significantly Improves Chronic Back Pain
AUG 07, 2022
Physiotherapy Technique Significantly Improves Chronic Back Pain
Sensorimotor retraining significantly improves pain intensity in chronic low back pain. The corresponding study was publ ...
Loading Comments...